The Promise of COVID-19 Hyperimmune Immune Globulin Therapy

As of this writing, NIAID and industry collaborators are also finalizing the design of a large-scale trial to assess whether COVID-Ig can reduce the rate of hospitalization and other medical encounters in earlier-stage COVID-19 patients exhibiting mild to moderate symptoms.

Infection Rates in PI Patients Decline with Increasing IVIG Dosages and IgG Trough Level

Titrating the IgG trough level up to 960 mg/dL progressively reduces the infection rate in PI patients, but there is less incremental benefit above this trough level.

Plasma Therapies: Effective COVID-19 Treatments?

Studies shed light on whether high-dose intravenous immune globulin, convalescent plasma and hyperimmune globulin will be effective therapeutic options for the novel coronavirus.

Stable and Durable Factor VIII Expression in Subjects Dosed with Investigational Hemophilia A Gene Therapy

More than two years after receiving Spark Therapeutics’ investigational adeno-associated virus (AAV)-mediated gene therapy (SPK-8011), five adult subjects with hemophilia A exhibited stable factor VIII (FVIII) expression, with no evidence of FVIII inhibitors or a cellular immune response.

Breakthroughs in Stem Cell Research

Optimism continues to grow about the use of stem cells in regenerative medicine highlighted by hundreds of successful clinical trials.

Large-Dose Albumin Supplementation Does Not Reduce Mortality or Need for Critical Care Interventions: Retrospective Review

Investigators conducted a retrospective review of 38 cases treated at Taipei Veterans General Hospital between January 2007 and December 2018 to determine whether more aggressive albumin supplementation can benefit major burn patients with persistent hypoalbuminemia.

Study Finds Safe Treatment for Children with Severe Hemophilia A with Inhibitors

Researchers have found combining immune tolerance induction (ITI) with Hemlibra (emicizumab, Roche) is a feasible and safe way of treating children with severe hemophilia A.

FDA Expands Indication for Octapharma’s WILATE to Hemophilia A

The U.S. Food and Drug Administration (FDA) has approved WILATE for treatment of adults and adolescents with hemophilia A for routine prophylaxis.

Medicare Will Now Cover Acupuncture for Chronic Low Back Pain

The Centers for Medicare and Medicaid Services (CMS) finalized a decision to cover acupuncture for Medicare patients with chronic low back pain.

Plasma-Derived ApoA-1

Findings suggest CSL112 can boost cholesterol efflux capacity in patients with impaired endogenous HDL function. Encouragingly, several studies have documented its ability to reduce atherosclerotic plaque volume.